Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) FCF Margin: 2020-2024

Historic FCF Margin for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to 7.71%.

  • Oncology Institute's FCF Margin fell 109100.0% to 9.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.01%, marking a year-over-year increase of 38900.0%. This contributed to the annual value of 7.71% for FY2024, which is 49000.0% up from last year.
  • Oncology Institute's FCF Margin amounted to 7.71% in FY2024, which was up 49000.0% from 12.61% recorded in FY2023.
  • Over the past 5 years, Oncology Institute's FCF Margin peaked at 0.37% during FY2020, and registered a low of 26.65% during FY2022.
  • Its 5-year average for FCF Margin is 12.97%, with a median of 12.61% in 2023.
  • As far as peak fluctuations go, Oncology Institute's FCF Margin tumbled by -171300bps in 2021, and later soared by 140400bps in 2023.
  • Over the past 5 years, Oncology Institute's FCF Margin (Annual) stood at 0.37% in 2020, then crashed by -4684bps to 17.5% in 2021, then tumbled by -52bps to 26.65% in 2022, then surged by 53bps to 12.61% in 2023, then skyrocketed by 39bps to 7.71% in 2024.
  • Its last three reported values are 7.71% in FY2024, 12.61% for FY2023, and 26.65% during FY2022.